December 8, 2022 Alnylam Named One of America's Most Responsible Companies by Newsweek Alnylam has been named one of America's Most Responsible Companies for 2023 by Newsweek and research firm Statista Read More ›
November 30, 2022 Alnylam Named #1 Largest Employer in MA for 2nd Year in a Row by The Boston Globe Alnylam is a Boston Globe Top Place to Work for the 8th consecutive year and the #1 ranked company on the "Largest Employers" list for the second year in a row Read More ›
October 26, 2022 Alnylam Named #2 Science Magazine Top Biopharma Employer Alnylam has been named the #2 Science Magazine Top Biopharma Employer for 2022, which marks our 4th year on the list. Read More ›
October 24, 2022 “Be the Link!” Learn from patients on World Amyloidosis Day No one knows this better than Jean-Christophe Fidalgo, President of the Amyloidosis Alliance, who has been living with hATTR amyloidosis for more than 20 years. Read More ›
September 27, 2022 Alnylam Named a Best Workplace for Women by Fortune Magazine Alnylam has been named a Fortune Best Workplace for Women for 2022 Read More ›
August 2, 2022 Alnylam Named #1 Best Workplace for Innovators by Fast Company Alnylam has been named the #1 Best Workplace for Innovators by Fast Company for 2022. Read More ›
July 13, 2022 Partnering with Nucleate to Support Young Biotech Entrepreneurs Alnylam is partnering with Nucleate to remove barriers for young biotech entrepreneurs... Read More ›
June 20, 2022 Challenging Ourselves to Help Refugees: Supporting Refugees to Become Work-Ready Alnylam has announced a three-year corporate partnership with Refugee Action, a United Kingdom (UK)-based charity dedicated to helping refugees... Read More ›
May 13, 2022 Hypertension: Charting A New Course to Address a Public Health Challenge Hypertension (high blood pressure) has seen limited medical innovation in recent history and remains a serious public health issue... Read More ›
May 9, 2022 Building a Collaborative Framework for Facilitating Patient Access to Innovative Therapies Alnylam worked with leading European economists and other healthcare experts to develop what we call the Value-Based Negotiation Framework (VBNF) to help... Read More ›

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site